Zura Bio Limited
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $398.6M
- Price
- $4.16
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.93%
- Volume
- 3.4M
About
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
Quick stats
Shares outstanding95.8M
Computed float21.9M
Float / shares22.9%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001855644
Websitehttps://zurabio.com
AI Summary
AI-generated1/11
minorneutralother
Zura Bio to Participate in the Cantor Global Healthcare Conference
Zura Bio management will attend the Cantor Global Healthcare Conference in New York on September 9, 2026.
The schedule includes a fireside chat at 9:10 a.m. ET, followed by one-on-one investor meetings with company leadership.
A live webcast of the presentation will be available on the company's website, with a replay accessible for 30 days.